Autoimmune Connect –
All Blogs
The NIH Report on Autoimmune Disease, Part 2: Enhancing Research
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
The NIH on Autoimmune Disease: An Invisible Epidemic
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
Some incidence, prevalence & growth estimates for selected autoimmune diseases (AIIDs)
We’ve compiled some incidence, prevalence and growth estimates for selected autoimmune diseases (AIIDs) as a follow up to our previous post. In that post, we surveyed the sorry state of US national autoimmune incidence & prevalence data. Summary: Per the May 2022 NIH Report: Enhancing Autoimmune Research the US has
Autoimmune Incidence & Prevalence: Why don’t we have good data on AIIDs?
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.
Stanford MedX Autoimmune 2014-17 Presentations by DrBonnie360
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Our pre-Covid vision of autoimmune business opportunities
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
The NIH Report on Autoimmune Disease, Part 2: Enhancing Research
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
The NIH on Autoimmune Disease: An Invisible Epidemic
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
Some incidence, prevalence & growth estimates for selected autoimmune diseases (AIIDs)
We’ve compiled some incidence, prevalence and growth estimates for selected autoimmune diseases (AIIDs) as a follow up to our previous post. In that post, we surveyed the sorry state of US national autoimmune incidence & prevalence data. Summary: Per the May 2022 NIH Report: Enhancing Autoimmune Research the US has
Autoimmune Incidence & Prevalence: Why don’t we have good data on AIIDs?
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.
Stanford MedX Autoimmune 2014-17 Presentations by DrBonnie360
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Our pre-Covid vision of autoimmune business opportunities
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within